Drug class
PCSK9 Inhibitors clinical trials
A class of medicines: the studies that test any of its 3 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the pcsk9 inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
189 studies that test it; most in 2019 (22); 4 more planned to start later
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 11 |
| 2012 | 18 |
| 2013 | 17 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 14 |
| 2017 | 14 |
| 2018 | 18 |
| 2019 | 22 |
| 2020 | 10 |
| 2021 | 17 |
| 2022 | 10 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 103 · Other 90
Amgen (40) · Sanofi (30) · Regeneron Pharmaceuticals (16) · LIB Therapeutics LLC (10) · Duke University (3) · Johns Hopkins University (3) · Brigham and Women's Hospital (2) · Insel Gruppe AG, University Hospital Bern (2)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 193
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingPhase 2Duke UniversityNCT06385262Written as Alirocumab
- CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACSRecruitingPhase 4West China HospitalNCT07612774Written as Evolocumab
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute PancreatitisRecruitingNot applicableGeneral Hospital of Shenyang Military RegionNCT07388420Written as Evolocumab 140 MG/ML [Repatha]
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNot yet recruitingPhase 4AmgenNCT07803679Written as Evolocumab
- RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque RemodelingNot yet recruitingPhase 4Keqiang ZhaoNCT07819643Written as Intervention 1
- Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial HypercholesterolemiaNot yet recruitingPhase 3LIB Therapeutics LLCNCT07775339Written as Lerodalcibep
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHEnrolling by invitationPhase 3LIB Therapeutics LLCNCT07102511Written as lerodalcibep 300 mg Monthly SC
- Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingPhase 1National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT04781322Written as Alirocumab
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingPhase 4University Medical Centre LjubljanaNCT07581808Written as Alirocumab
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid PlaqueNot yet recruitingPhase 3Middle East North Africa Stroke and Interventional Neurotherapies OrganizationNCT07586540Written as Alirocumab
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAANot yet recruitingEarly Phase 1University of PennsylvaniaNCT06081153Written as Evolocumab
- PCSK9 Inhibitors in the Treatment of Calcific Aortic StenosisNot yet recruitingPhase 3Beijing Anzhen HospitalNCT07256197Written as Treatment with PCSK9 inhibitors
- Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium InfarctionRecruitingPhase 4Shanghai Tong Ren HospitalNCT05292404Written as alirocumab
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1RecruitingPhase 4NYU Langone HealthNCT05641753Written as Evolocumab Cartridge
- The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV RiskRecruitingPhase 4Brigham and Women's HospitalNCT05152888Written as Evolocumab
- A Study on Evaluating the Safety of HST101 in Healthy Chinese ParticipantsEnrolling by invitationPhase 1Hasten Biopharmaceutical Co., Ltd.NCT06504043Written as HST101
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingPhase 3Hasten Biopharmaceutical Co., Ltd.NCT06568471Written as Lerodalcibep
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationPhase 3LIB Therapeutics LLCNCT04798430Written as lerodalcibep
- Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial InfarctionRecruitingNot applicableBeijing Luhe HospitalNCT06364124Written as evolocumab
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran